Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqCM:RZLT
Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Rezolute, Inc. (NASDAQ:RZLT) Chief Financial Officer, Daron Evans, recently bought US$53k worth of stock, for US$5.04 per share. However, it only increased their shares held by 6.5%, and it wasn't a huge purchase by absolute value, either.
See our latest analysis for Rezolute
The Last 12 Months Of Insider Transactions At Rezolute
Notably, that recent purchase by Chief Financial Officer Daron Evans was not the only time they bought Rezolute shares this year. They previously made an even bigger purchase of US$96k worth of shares at a price of US$1.93 per share. We do like to see buying, but this purchase was made at well below the current price of US$4.64. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
While Rezolute insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Does Rezolute Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Rezolute insiders own 0.9% of the company, worth about US$2.4m. I generally like to see higher levels of ownership.
What Might The Insider Transactions At Rezolute Tell Us?
The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Rezolute insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Rezolute. At Simply Wall St, we've found that Rezolute has 3 warning signs (1 is a bit unpleasant!) that deserve your attention before going any further with your analysis.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:RZLT
Rezolute
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.